Literature DB >> 34187748

Number of cores needed to diagnose prostate cancer during MRI targeted biopsy decreases after the learning curve.

Mark D Bevill1, Victoria Troesch2, Justin N Drobish1, Kevin J Flynn1, Maheen Rajput3, Catherine M Metz3, Paul T Gellhaus1, Chad R Tracy4.   

Abstract

INTRODUCTION: We hypothesized that the number of cores needed to detect prostate cancer would decrease with increasing MRI-targeted biopsy (TBx) experience.
METHODS: All patients undergoing TBx at our institution from May 2017 to August 2019 were enrolled in a prospectively maintained database. Five biopsy cores were obtained from each lesion ≥3 on PI-RADS v2.0 followed by a systematic 12-core biopsy. To assess learning curve, the study population was divided into quartiles by sequential biopsies. Clinically significant prostate cancer (csPC) was defined as Gleason Grade Group 2 or higher.
RESULTS: 377 patients underwent prostate biopsy (533 lesions); 233 lesions (44%) were positive for prostate cancer and 173 lesions (32%) were csPC. There was a significant decline in the number of cores required for diagnosing any cancer (P < 0.001) and csPC (P < 0.05) after the first quartile. There was no difference when stratifying by PI-RADS score or lesion volume. Within the first quartile, limiting the biopsy to 3 cores would miss 16.2% of csPC, decreasing to 6.6% after approximately 100 patients.
CONCLUSION: MRI TBx is associated with a learning curve of approximately 100 cases. Four or 5 cores should be considered during the initial experience, but thereafter, 3 cores per lesion is sufficient to detect csPC.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Learning curve; Mri; Prostate cancer; Targeted biopsy

Mesh:

Year:  2021        PMID: 34187748     DOI: 10.1016/j.urolonc.2021.05.029

Source DB:  PubMed          Journal:  Urol Oncol        ISSN: 1078-1439            Impact factor:   3.498


  1 in total

1.  Single center analysis of an advisable control interval for follow-up of patients with PI-RADS category 3 in multiparametric MRI of the prostate.

Authors:  M Boschheidgen; L Schimmöller; S Doerfler; R Al-Monajjed; J Morawitz; F Ziayee; D Mally; M Quentin; C Arsov; P Albers; G Antoch; T Ullrich
Journal:  Sci Rep       Date:  2022-04-25       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.